Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Fox Corp Class B (FOX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Fox Corp Class B — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $280.45 (market cap $39.89B), while Fox Corp Class B trades at $49.99 (market cap $21.54B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Fox Corp Class B pays a 1.15% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | FOX | |
|---|---|---|
Market Cap | $39.89B | $21.54B |
Sector | Health | Media |
52-Week High | $491.22 | $67.76 |
52-Week Low | $278.09 | $44.39 |
Enterprise Value | $38.15B | $25.51B |
Dividend Yield | — | 1.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
FOX stock trades at $48.75, up 0.64% today, amid a bearish technical signal but strong fundamental performance. Recent quarters show consistent earnings beats, with Q2 2026 EPS expected at $1.41. The company's 2025 revenue surged to $16.3B, driving net income to $2.26B, while cash flow turned positive at $1.03B. Key developments include the $22B Roku acquisition, highlighting strategic moves in streaming, though leverage concerns have pressured the stock, which is down 25% over four weeks as of June 26, 2026 (Zacks Investment Research).
The outlook balances robust fundamentals against near-term headwinds. Valuation appears attractive with a P/E of 12.83 and EV/EBITDA of 8.19, but integration risks from the Roku deal and bearish technical trends pose challenges. Analyst consensus is mixed (42.86% Buy, 47.62% Hold), suggesting cautious optimism for long-term growth driven by streaming expansion and advertising recovery, though volatility may persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →
